Barrett Asset Management LLC increased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 2.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 113,866 shares of the biopharmaceutical company’s stock after purchasing an additional 3,115 shares during the period. Barrett Asset Management LLC’s holdings in Celgene were worth $16,604,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Capital Counsel LLC NY boosted its stake in Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC boosted its stake in Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 11 shares in the last quarter. Savant Capital LLC boosted its stake in Celgene by 0.9% in the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. boosted its stake in Celgene by 0.9% in the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after acquiring an additional 26 shares in the last quarter. Finally, Granite Investment Advisors LLC boosted its stake in Celgene by 1.1% in the second quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 78.93% of the company’s stock.

Get Celgene alerts:

In related news, insider Mark J. Alles bought 3,260 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were acquired at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the transaction, the insider now directly owns 178,904 shares in the company, valued at $16,441,277.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.95% of the stock is owned by company insiders.

Several equities research analysts have weighed in on CELG shares. Royal Bank of Canada lowered their target price on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating for the company in a research note on Friday, October 27th. Leerink Swann restated a “buy” rating and issued a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley decreased their price target on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating for the company in a report on Monday, October 23rd. Mizuho reaffirmed a “buy” rating and issued a $128.00 price target on shares of Celgene in a report on Sunday, February 4th. Finally, SunTrust Banks decreased their price target on shares of Celgene from $156.00 to $127.00 and set a “buy” rating for the company in a report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $130.35.

Celgene Co. (NASDAQ CELG) traded up $1.49 during mid-day trading on Friday, reaching $92.51. 10,465,217 shares of the company traded hands, compared to its average volume of 8,240,000. The firm has a market capitalization of $69,580.00, a price-to-earnings ratio of 25.63, a PEG ratio of 0.66 and a beta of 1.49. The company has a current ratio of 4.99, a quick ratio of 3.52 and a debt-to-equity ratio of 2.29. Celgene Co. has a 52 week low of $88.32 and a 52 week high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm’s revenue was up 16.9% on a year-over-year basis. During the same quarter last year, the business earned $1.61 earnings per share. research analysts predict that Celgene Co. will post 7.68 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Barrett Asset Management LLC Acquires 3,115 Shares of Celgene Co. (CELG)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2018/02/12/barrett-asset-management-llc-has-16-60-million-holdings-in-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.